\
&
Contact us
\
&
Contact us
Published on | 10 months ago
Programmes Digital, Industry & Space Digital Europe Cybersecurity Defence EDFThere are 4 attachments connected to this article.
Attachments are only accessible for people with an account on the NCP Flanders website.
We would like to inform you that the Commission has adopted and published the European Defence Fund Work Programme 2025.
The news announcement (with links to the documents and a factsheet) is available on DEFIS website: https://defence-industry-space.ec.europa.eu/european-defence-fund-over-eu1-billion-drive-next-generation-defence-technologies-and-innovation-2025-01-30_en; a post on DEFIS X account: https://x.com/defis_eu/status/1884919494713197039
The documents are available directly at https://defence-industry-space.ec.europa.eu/edf-work-programme-2025_en or attached to this newsitem or on our NCP Flanders website.
We would also like to remind you of the EDF Info Day on February 21st!
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
